Apremilast has been prescribed to more than 250,000 patients with plaque psoriasis or psoriatic arthritis since it was approved in 2014.
Kenny Walter
Advertisement
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Articles by Kenny Walter
An international survey shows an increase in telemedicine, but a decrease in out-patient care.
The treatment is the first approved medication for this patient population.
The VELYS Robotic-Assisted solution will be used in conjunction with the VELYS Digital Surgery Platform.
Risk of herpes zoster and creatine phosphokinase increased with use of upadacitinib.
Gilead expects topline results available from a pair of trials testing the new treatment in 2021.
Guselkumab represents the first FDA approved medication for active psoriatic arthritis that selectively inhibits interleukin-23.
The approval is based on the phase 3 PREVENT trial, presented at the European E-Congress of Rheumatology 2020 (EULAR 2020) virtual meeting.
Canakinumab was previously approved for the treatment of Systemic Juvenile Idiopathic Arthritis.
Dr. Richard Furie explains the link between systemic lupus erthematosus and COVID-19.
Dr. Vibeke Strand discusses the relationship between COVID-19 and psoriatic arthritis.
Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.
Dr. Philip Mease explains the next steps for testing the efficacy and safety of upadacitinib for patients with psoriatic arthritis.
Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.
Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.
Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.
Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.
Study drug also recently showed promise in treating psoriatic arthritis.
Remission and LDA rates generally increased over time in patients with psoriatic arthritis receiving tofacitinib.
Asian countries regularly see higher rates of SLE prevalence globally.
In a late-breaking abstract, investigators test nanoparticle treatment using in vivo models.
In an abstract presented at EULAR 2020, investigators find more serious adverse events in the upadacitinib treatment arms compared to placebo.
Dr. Gregg Silverman said identification of Ruminococcus gnavus could allow earlier diagnosis of lupus nephritis.
In a study presented at EULAR, investigators find 14-3-3η baseline levels did not correlate with baseline mTSS.
In both DISCOVER trials, investigators find guselkumab effective against active psoriatic arthritis domains.
The treatment has already proven to reduce oral ulcers associated with Behcet’s syndrome.
There are currently 14 antiviral medications being tested as possible treatments for COVID-19.
Mortality rates do not increase for inflammatory bowel disease patients who are exposed to JAK inhibitors.
In a new study, investigators show belimumab as a treatment could normalize or stabilize proteinuria is patients with lupus nephritis.
Abdul Abdellatif, MD, discusses during Kidney Week some treatment options for patients with gout.
Advertisement
Advertisement
Advertisement